A Double Blind (3rd Party Open) Randomized, Placebo Controlled, Crossover Dose Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics of PF-06305591 in Healthy Male and Female Subjects
Phase of Trial: Phase I
Latest Information Update: 22 May 2013
At a glance
- Drugs PF 6305591 (Primary)
- Indications Pain
- Focus Adverse reactions
- 01 May 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 03 Apr 2013 Planned End Date changed from 1 Mar 2013 to 1 May 2013 as reported by ClinicalTrials.gov record.
- 07 Mar 2013 New trial record